According to CEO of Serum Institute of India (SII), Poonawalla, the first quadrivalent Human Papilloma Virus (qHPV) vaccine for preventing cervical cancer, which is slated to hit the market in the coming months, will likely cost between Rs 200 and Rs 400.
It will probably cost between $200 and $400. However, we won't finalise anything until we've had a conversation with the Indian administration. We will be able to discuss it further once our manufacturing begins. Everyone may rest assured that it will be extremely reasonably priced. According to Poonawalla, it will be significantly less expensive than what is currently offered by manufacturers all over the world. He was speaking at an event to announce the creation of the vaccine.
The quadrivalent vaccination (Gardasil Merck), which costs Rs 2,800 per dosage, and the bivalent vaccine (Cervarix from GlaxoSmithKline), which costs Rs 3,299 per dose, are the two HPV vaccines now offered in India by international producers.